Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - zdravila za obstruktivne pljučne bolezni, - fasenra je indicirano kot dodatek na vzdrževanje zdravljenje pri odraslih bolnikih s hudo eozinofilno astmo neustrezno nadzorovano kljub visoki odmerki vdihavajo kortikosteroide plus dolgo delujoči beta agonistov.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - natrijev cirkonij cyclosilicate - hiperkalemija - vsi drugi terapevtski izdelki - lokelma je primerna za zdravljenje hyperkalaemia pri odraslih bolnikih,.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, pljučni pljuč - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pljučna bolezen, kronična obstruktivna bolezen - formoterol in glycopyrronium bromid - bevespi aerosphere je označen kot vzdrževanje bronchodilator zdravljenje za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno bolezen (kopb).

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - drog stranske učinke in neželene učinke - vsi drugi terapevtski izdelki - pri odraslih bolnikih z neposrednim faktorja xa (fxa) serotonina (apixaban ali rivaroxaban), ko odprave antikoagulacijo je potrebna zaradi smrtno nevarno ali nenadzorovana krvavitev.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - metformin hidroklorid, saxagliptin, dapagliflozin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - qtrilmet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzora, ko je z metforminom ali brez sulfonil sečnine (su) in bodisi saxagliptin ali dapagliflozin ne zagotavlja primerne glycaemic nadzor. ko se že zdravijo z metforminom in saxagliptin in dapagliflozin.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pljučna bolezen, kronična obstruktivna bolezen - zdravila za obstruktivne pljučne bolezni, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - levkemija, limfocitna, kronična, b-celica - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemija, dlakasta celica - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.